The phase Ib trial provides evidence that the combination of local radiotherapy with NHS-IL2 is well tolerated, and the limited antitumor activity data suggest that a small cohort of NSCLC patients might benefit from this treatment. The gene discussed is IL2; the disease is non-small cell lung carcinoma.